“The potential to deliver ‘one shot cures’ is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies,” analyst Salveen Richter wrote in the note to clients Tuesday. “While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.”
I feel like the person who wrote this is fully aware of the nature of the problem here. I bet most medical researchers very much want to be a part of permanently curing diseases. They just can’t because their job is to make money for a company.
Patients who are cured go on to live a longer more productive life and spend more in other sectors (including checkups and visits for later issues). So yeah, heartless dumbasses, it’s good.
Add comment